OBJECTIVE: To determine whether children aged 3-59 months with mild or non-symptomatic human immunodeficiency virus (HIV) infection and WHO-defined severe pneumonia have a higher failure rate than do HIV-uninfected children when treated with the standard WHO treatment of parenteral penicillin or oral amoxicillin. METHODS: This study was a planned sub-analysis of a randomized trial of 3-59-month-old children presenting with WHO-defined severe pneumonia (the APPIS study). We included two sites with high HIV prevalence in Durban, South Africa and Ndola, Zambia. Primary outcome measures were clinical treatment failure at day 2 and day 14. CLINICALTRIALS.GOV IDENTIFIER: CT00227331http://www.clinicaltrialsgov/show/NCT00227331). FINDINGS: Of the 523 children enrolled, HIV status was known for 464 participants; 106 (23%) of these were infected with HIV. By day 2, 57 (12.3%) children had failed treatment and 110 (23.7%) failed by day 14. Twenty (18.9%) HIV-infected children failed by day 2 compared with 37 (10.3%) uninfected children (adjusted odds ratio (OR) 2.07; 95% confidence interval (CI): 1.07-4.00). Thirty-four (32.1%) HIV-infected children failed treatment by day 14 compared with 76 (21.2%) uninfected children (adjusted OR 1.88; 95% CI: 1.11-3.17). Analysis stratified by age showed that the greatest differential in treatment failure at day 2 and day 14 occurred in the children aged 3-5 months. CONCLUSIONS:HIV-infected children with severe pneumonia fail WHO-standard treatment withparenteral penicillin or amoxicillin at day 2 and day 14 more often than do HIV-uninfected children, especially young infants. Standard case management of acute respiratory infection (ARI) using WHO treatment guidelines is inadequate in areas of high HIV prevalence and reappraisal of empiric antimicrobial therapy is urgently needed for severe pneumonia associated with HIV-1.
RCT Entities:
OBJECTIVE: To determine whether children aged 3-59 months with mild or non-symptomatic human immunodeficiency virus (HIV) infection and WHO-defined severe pneumonia have a higher failure rate than do HIV-uninfectedchildren when treated with the standard WHO treatment of parenteral penicillin or oral amoxicillin. METHODS: This study was a planned sub-analysis of a randomized trial of 3-59-month-old children presenting with WHO-defined severe pneumonia (the APPIS study). We included two sites with high HIV prevalence in Durban, South Africa and Ndola, Zambia. Primary outcome measures were clinical treatment failure at day 2 and day 14. CLINICALTRIALS.GOV IDENTIFIER: CT00227331http://www.clinicaltrialsgov/show/NCT00227331). FINDINGS: Of the 523 children enrolled, HIV status was known for 464 participants; 106 (23%) of these were infected with HIV. By day 2, 57 (12.3%) children had failed treatment and 110 (23.7%) failed by day 14. Twenty (18.9%) HIV-infectedchildren failed by day 2 compared with 37 (10.3%) uninfected children (adjusted odds ratio (OR) 2.07; 95% confidence interval (CI): 1.07-4.00). Thirty-four (32.1%) HIV-infectedchildren failed treatment by day 14 compared with 76 (21.2%) uninfected children (adjusted OR 1.88; 95% CI: 1.11-3.17). Analysis stratified by age showed that the greatest differential in treatment failure at day 2 and day 14 occurred in the children aged 3-5 months. CONCLUSIONS:HIV-infectedchildren with severe pneumonia fail WHO-standard treatment with parenteral penicillin or amoxicillin at day 2 and day 14 more often than do HIV-uninfectedchildren, especially young infants. Standard case management of acute respiratory infection (ARI) using WHO treatment guidelines is inadequate in areas of high HIV prevalence and reappraisal of empiric antimicrobial therapy is urgently needed for severe pneumonia associated with HIV-1.
Authors: Clare Webb; Mwanajuma Ngama; Anthony Ngatia; Mohammed Shebbe; Susan Morpeth; Salim Mwarumba; Ann Bett; D James Nokes; Anna C Seale; Sidi Kazungu; Patrick Munywoki; Laura L Hammitt; J Anthony G Scott; James A Berkley Journal: Pediatr Infect Dis J Date: 2012-09 Impact factor: 2.129
Authors: Matthew P Fox; Donald M Thea; Salim Sadruddin; Abdul Bari; Rachael Bonawitz; Tabish Hazir; Yasir Bin Nisar; Shamim A Qazi Journal: Clin Infect Dis Date: 2012-12-21 Impact factor: 9.079
Authors: Rasa Izadnegahdar; Matthew P Fox; Prakash Jeena; Shamim A Qazi; Donald M Thea Journal: Pediatr Infect Dis J Date: 2014-01 Impact factor: 2.129
Authors: Carina King; Eric D McCollum; Limangeni Mankhambo; Tim Colbourn; James Beard; Debbie C Hay Burgess; Anthony Costello; Rasa Izadnegahdar; Raza Izadnegahdar; Norman Lufesi; Gibson Masache; Charles Mwansambo; Bejoy Nambiar; Eric Johnson; Robert Platt; David Mukanga Journal: PLoS One Date: 2015-08-27 Impact factor: 3.240
Authors: Evropi Theodoratou; David A McAllister; Craig Reed; Davies O Adeloye; Igor Rudan; Lulu M Muhe; Shabir A Madhi; Harry Campbell; Harish Nair Journal: Lancet Infect Dis Date: 2014-11-12 Impact factor: 25.071